Gabelli Funds LLC Sells 12,900 Shares of Abbott Laboratories $ABT

Posted by George Bondi on Jul 29th, 2026

Gabelli Funds LLC cut its holdings in Abbott Laboratories (NYSE:ABT – Free Report) by 22.3% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 44,900 shares of the healthcare product maker’s stock after selling 12,900 shares during the quarter. Gabelli Funds LLC’s holdings in Abbott Laboratories were worth $4,610,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of ABT. Freemont Management S.A. increased its stake in Abbott Laboratories by 197.2% during the fourth quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock worth $1,341,000 after acquiring an additional 7,100 shares during the last quarter. PFA Pension Forsikringsaktieselskab purchased a new stake in Abbott Laboratories during the fourth quarter valued at approximately $116,580,000. Thrivent Financial for Lutherans lifted its stake in shares of Abbott Laboratories by 24.3% in the 4th quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock valued at $30,931,000 after purchasing an additional 48,286 shares during the last quarter. Mn Services Vermogensbeheer B.V. boosted its holdings in shares of Abbott Laboratories by 2.1% in the 4th quarter. Mn Services Vermogensbeheer B.V. now owns 671,743 shares of the healthcare product maker’s stock worth $84,163,000 after purchasing an additional 13,543 shares during the period. Finally, Aureus Asset Management LLC increased its position in shares of Abbott Laboratories by 25.0% during the 1st quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker’s stock valued at $34,078,000 after purchasing an additional 66,422 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: Quarterly beat and raised guidance support investor confidence. Abbott reported second-quarter earnings of $1.31 per share, above the $1.28 consensus estimate, while revenue rose 13% year over year to $12.59 billion. Management raised its fiscal 2026 EPS outlook to $5.45-$5.60 and expects third-quarter EPS of $1.38-$1.46. Strong demand for cancer diagnostics and medical devices helped offset concerns about procedure volumes. Abbott Raised Its Profit Forecast
Positive Sentiment: Growth initiatives provide multiple expansion paths. Abbott is investing in diabetes care, oncology diagnostics and cardiovascular devices through new product launches and acquisitions, giving investors several potential sources of future sales growth. Abbott Rides Key Diabetes, Oncology and Heart Care Innovation Trends
Positive Sentiment: New colorectal cancer screening rights strengthen Abbott’s diagnostics portfolio. Abbott secured exclusive U.S. commercialization rights for Freenome’s FDA-cleared SimpleScreen blood-based colorectal cancer test. The product could broaden screening access, particularly among Americans overdue for testing, although commercial adoption will determine the financial impact. FDA Approves Freenome’s SimpleScreen CRC Test
Neutral Sentiment: Analysts remain constructive but see limited valuation upside. UBS lowered its ABT price target from $135 to $125 while maintaining a Buy rating, implying meaningful upside from the referenced trading level. Another analysis noted that Abbott’s earnings setup has improved, but its elevated valuation could constrain returns. UBS Abbott Price Target Update
Negative Sentiment: Guidance and litigation concerns remain overhangs. Despite the earnings beat and improved outlook, investors continue to monitor legal risks and whether projected growth will justify Abbott’s premium earnings multiple. Abbott Fell as Guidance and Litigation Concerns Overshadowed Growth

Analyst Ratings Changes

Several research firms recently weighed in on ABT. Leerink Partners decreased their price target on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a report on Tuesday, April 21st. Wells Fargo & Company boosted their price objective on shares of Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. Raymond James Financial reduced their target price on shares of Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. The Goldman Sachs Group lowered their target price on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a report on Wednesday, May 27th. Finally, Barclays cut their price target on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a report on Monday, April 20th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $118.17.

Check Out Our Latest Stock Analysis on Abbott Laboratories

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock opened at $107.34 on Wednesday. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49. The company has a market capitalization of $186.97 billion, a PE ratio of 34.74, a price-to-earnings-growth ratio of 2.02 and a beta of 0.61. The stock’s fifty day moving average is $92.32 and its two-hundred day moving average is $100.85. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The firm had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. The business’s revenue was up 13.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is 81.55%.

Abbott Laboratories Profile

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.